In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising...
Read More
In a nutshell This study aimed to investigate the long-term outcomes of venetoclax and rituximab (VR) treatment in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL). This study concluded that this treatment had long-term effectiveness in these patients. Some background Bendamustine...
Read More
In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL). This study concluded that both treatments are safe and effective as a...
Read More
In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia who were resistant or intolerant to imatinib in daily clinical practice. This study concluded that dasatinib is safe and effective in these patients. Some background...
Read More
In a nutshell This study aimed to investigate two pre-transplant conditioning regimes for patients with acute myeloid leukemia. This study concluded that total body irradiation and fludarabine (Fludara) may be a suitable reduced toxicity conditioning treatment option for these patients. Some background A conditioning...
Read More
In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma. This study concluded that this treatment path is feasible and a good alternative for these patients. Some background Allogenic hemopoietic...
Read More
In a nutshell This study aimed to compare outcomes of salvage chemotherapy for patients with relapsed or refractory acute myeloid leukemia. This study concluded that the CLAG-M regimen (cladribine, cytarabine, filgrastim, and mitoxantrone) followed by transplant is a suitable salvage treatment for these patients. Some...
Read More
In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA). This study concluded that this treatment option was safe and effective for patients with...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML). This study...
Read More
In a nutshell This study aimed to investigate three different chemotherapy-free treatment regimens for patients with chronic lymphocytic leukemia. This study concluded that acalabrutinib (Calquence) plus obinutuzumab (Gazyva) improved survival without cancer worsening for these patients. Some background Chemotherapy-free...
Read More
In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...
Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read More
